Dr. Reddy’s Q1 Results Review: Systematix Maintains ‘Hold’ Rating On Weak U.S. Performance
Dr. Reddy’s Laboratories Ltd.’s Q1 FY26 results were below estimates due to weaker-than-expected performance in North America, led by price erosion and lower offtake for gRevlimid.